April 2026 Research Update

In a small, closely followed group of pregnancies in women with confirmed or suspected vascular Ehlers-Danlos syndrome (vEDS), the most striking finding was stability of the aorta during pregnancy, alongside a mix of maternal and fetal outcomes. No maternal deaths or aortic dissections were reported in this series, and the aorta did not show significant growth during pregnancy, which adds a cautious bit of reassurance about one specific concern that is often monitored. At the same time, obstetric complications were common, showing that pregnancy can still be medically complex even when the aorta appears stable in measurements. [1]

This report described 6 pregnancies from the ROPAC III registry and tracked both clinical outcomes and aortic measurements over time. Most deliveries were by cesarean section, and complications like preterm birth and hemorrhage were reported, with one fetal death in the series. Because the group was very small and included both confirmed and suspected vEDS, the results should be read as an early description of what happened in these pregnancies, not a guarantee of risk levels for everyone. [1]

For patients and families, this month adds a clearer (but still early) picture that aortic size may remain fairly stable during pregnancy for some people with vEDS when it is measured over time, while other pregnancy-related complications can still occur. This is based on a small case series, so it is mainly useful for understanding what has been observed so far rather than changing decisions or expectations on its own. What remains uncertain is how these results apply across different genetic variants, levels of baseline risk, and different care settings, since the report does not establish who is most likely to have a smooth course. [1]

This month included individual reports of less expected vessel and lung problems in people with confirmed or suspected vEDS, and how teams sometimes try to balance getting answers with avoiding procedures that could cause bleeding. One report focused on a complex splenic artery problem, in a woman suspected of having vEDS, treated using a minimally invasive approach to block abnormal blood flow while preserving nearby circulation. Another report focused on unusual-looking lung lesions that were ultimately interpreted as bleeding inside the lungs related to fragile blood vessels, after extensive testing did not identify another cause. [2] [3]

In the splenic artery case, a 28-year-old woman with suspected vEDS had an aneurysm and a high-flow arteriovenous fistula, and the team used dual balloons plus coils and NBCA glue (a liquid embolization material) to control blood flow during treatment. The report described successful exclusion of the abnormal connection on follow-up imaging, while maintaining hepatic and portal venous flow and keeping the spleen tissue viable. As a single case, it mainly shows what was feasible for this one patient rather than how often this approach works or what the typical risks are. [2]

In the lung case, a 30-year-old man with a COL3A1 pathogenic variant had a large cavitary lung lesion and multiple nodules, and extensive imaging and tests did not give a clear infectious, immune, or cancer explanation. Because of concern about bleeding risk, invasive sampling was avoided, and the final interpretation was that these findings represented intrapulmonary hematomas (bleeding within the lung) due to vascular fragility in vEDS. This report adds to awareness that lung imaging in vEDS can look alarming and still reflect bleeding-related changes rather than a separate disease, although it cannot tell how common this is. [3]

For patients, these case reports mainly broaden the picture of how vEDS-related vessel fragility can appear in different organs and how careful planning may be used to reduce procedure-related risk in certain situations. They do not establish a standard approach, but they help clarify that some complex findings (like certain lung lesions) may sometimes be explained by bleeding from fragile vessels, and that some vascular problems may be treated with catheter-based techniques in selected cases. What remains uncertain is how often these presentations occur, how reliably they can be recognized without invasive testing, and how outcomes compare across different treatment options, since single-patient reports cannot answer those questions. [2] [3]

A mouse study this month adds an early research signal that puberty-related hormone pathways may influence aortic rupture risk in a model of vEDS, and that blocking certain hormone receptors can reduce risk in that model. The study reported that stopping androgen receptor (AR) signaling removed male-female survival differences, and a drug that blocks both AR and mineralocorticoid receptor (MR) signaling gave near-complete protection in both sexes. This helps narrow in on specific biological pathways that might matter for future therapies, while still being far from proving benefit in people. [4]

The same mouse work also reported that targeting MR signaling alone was effective, and the authors noted this might avoid male-specific side effects linked to AR blockade. The study connected these effects to changes in gene programs related to the extracellular matrix, which is part of how blood vessel walls maintain strength. Because this is animal research, it should be seen as a step toward understanding mechanisms and generating treatment ideas rather than evidence that these approaches prevent events in patients. [4]

For patients and caregivers, this is mainly early-stage research that may matter later if similar effects are shown in human studies. What it helps clarify now is that sex-related differences seen around puberty in a vEDS mouse model may be tied to specific hormone receptors, and that changing those signals can strongly shift outcomes in that model. What remains uncertain is whether the same pathways drive risk in people with vEDS, and whether medicines that affect AR or MR signaling would be safe or helpful in human vEDS without careful study. [4]